Australia's most trusted
source of pharma news
Monday, 07 October 2024
Posted 30 September 2024 AM
The TGA has confirmed that Apellis' eye drug Syfovre is still being considered and that no decision has yet been made after Europe's advisory committee, the CHMP, refused granting the company marketing authorisation yet again this month.
Last week, the CHMP confirmed its initial recommendation to refuse the granting of a marketing authorisation for Syfvore, crushing Apellis' hopes to bring the first treatment for geographic atrophy (GA) to market in Europe.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.